Influence of antigen density and TLR ligands on preclinical efficacy of a VLP-based vaccine against peanut allergy.

S Krenger, Pascal; Josi, Romano; Sobczak, Jan; L C Velazquez, Thalia; Balke, Ina; A Skinner, Murray; F Kramer, Matthias; J W Scott, Callum; Hewings, Simon; D Heath, Matthew; Zeltins, Andris; F Bachmann, Martin

doi:10.1111/all.15897

Public

Influence of antigen density and TLR ligands on preclinical efficacy of a VLP-based vaccine against peanut allergy.

Shared by NobleBlocks on Jan 1, 2024 • 12:00 AM UTC

Authors:

Pascal S Krenger

Romano Josi

Jan Sobczak

Abstract

BACKGROUND: Virus-like particle (VLP) Peanut is a novel immunotherapeutic vaccine candidate for the treatment of peanut allergy. The active pharmaceutical ingredient represents cucumber mosaic VLPs (CuMVTT -VLPs) that are genetically fused with one of the major peanut allergens, Ara h 2 (CuMVTT -Ara...

Subject

allergy treatment

food allergy

immunotherapy vaccines and mechanisms

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!